Dahlöf C
Gothenburg Migraine Clinic, Sweden.
Cephalalgia. 1993 Jun;13(3):166-71. doi: 10.1046/j.1468-2982.1993.1303166.x.
Although oral ergotamine alone or in combination with caffeine is widely used for the acute treatment of migraine, there is little evidence that it is significantly more effective than placebo. There are no placebo-controlled data to support the use of aerosol or suppository formulations. In addition, the recommended doses of ergotamine cannot be justified. Each formulation of ergotamine now should be tested in clinical studies performed according to the IHS criteria for trial design and in migraine patients fulfilling the diagnostic criteria of the IHS. Until these clinical data are available, no clear recommendations can be given for the use of ergotamine in the acute treatment of migraine.
尽管单独使用口服麦角胺或与咖啡因联合使用被广泛用于偏头痛的急性治疗，但几乎没有证据表明它比安慰剂显著更有效。没有安慰剂对照数据支持使用气雾剂或栓剂剂型。此外，麦角胺的推荐剂量缺乏依据。现在，每种麦角胺制剂都应在根据国际头痛协会（IHS）试验设计标准进行的临床研究中，并在符合IHS诊断标准的偏头痛患者中进行测试。在获得这些临床数据之前，无法就麦角胺在偏头痛急性治疗中的使用给出明确建议。
